The US Food and Drug Administration (FDA) has rejected PTC Therapeutics’ new drug application (NDA) for vatiquinone in ...

PTC Therapeutics has long been trying to workshop its vatiquinone into a marketable treatment for Friedreich's ataxia (FA) after a phase 3 fail in 2023. | Despite missing its primary endpoint in a ...

The FDA said data for PTC's drug did not prove "substantial evidence of efficacy." Elsewhere, the FDA delayed its decision on ...

The small molecule, vatiquinone, had already flunked a Phase III trial, but the company pushed ahead with an approval bid ...

FDA rejected PTC Therapeutics' vatiquinone for Friedreich's ataxia, citing insufficient efficacy data and requiring another ...

The U.S. Food and Drug Administration has denied approval for PTC Therapeutics' oral medication for a rare genetic disorder ...

The U.S. Food and Drug Administration has declined to approve PTC Therapeutics' drug to treat a rare genetic disorder with ...

PTC is demonstrating robust growth and consistent profitability, and analyst sentiment has grown more favorable recently.

This was the stock's second consecutive day of losses.

PTC announced the acquisition of the cloud-native computer-aided Manufacturing (CAM) solution, CloudMilling. Terms of the transaction were not disclosed. The UK-based father and son team, which ...

PTC outraged by ‘Nip/Tuck’ self-mutilation Time for another example of moral outrage from the Parents Television Council. Earlier this month, the PTC was horrified that NBC accidentally showed ...